Cargando…
A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia
BACKGROUND: New therapies are urgently needed for Alzheimer’s disease (AD). Sodium oligomannate (GV-971) is a marine-derived oligosaccharide with a novel proposed mechanism of action. The first phase 3 clinical trial of GV-971 has been completed in China. METHODS: We conducted a phase 3, double-blin...
Ejemplares similares
-
A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia
por: Wang, Tao, et al.
Publicado: (2020) -
Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression
por: Wang, Xinyi, et al.
Publicado: (2019) -
Sodium oligomannate combined with rivastigmine may improve cerebral blood flow and cognitive impairment following CAR-T cell therapy: A case report
por: Wang, Yan-Li, et al.
Publicado: (2022) -
Pharmacokinetics, distribution, and excretion of sodium oligomannate, a recently approved anti-Alzheimer's disease drug in China
por: Lu, Jiaojiao, et al.
Publicado: (2022) -
Efficacy and safety of rasagiline in Chinese patients with early Parkinson’s disease: a randomized, double-blind, parallel, placebo-controlled, fixed-dose study
por: Zhang, Zhenxin, et al.
Publicado: (2018)